2021 has been an outstanding year for us at the Childhood Cancer & Blood Disorders Group. In 2021, Dr Lucas Moreno took over the leadership of the group. We also updated our group's name to represent all our research areas including paediatric cancers and non-malignant haematological conditions where our group plays a leading role such us red blood cell disorders, advanced therapies and stem cell transplantation among others. Our scientific production continued to increase, with key clinical practice-changing high impact publications in the fields of allogeneic stem cell transplantation, leukaemia, solid tumours and targeted therapies. We also secured funding from several competitive national and international projects led by our group's members. Our clinical trial activity increased with 40+ early-phase trials open for recruitment. Moreover, we are proud to work side by side with patient-led organisations as relevant stakeholders to fulfill our group's objectives.

Group Leader
Lucas Moreno Martín-Retortillo

Principal Investigator (PI)
M. Mar Mañu Pereira, Josep Roma Castanyer, Miguel F Segura Ginard, Anna Llort Sales, M Cristina Díaz de Heredia Rubio and Aroa Soriano Fernández

Researchers
Laura Alonso García, Roberta Antonelli, Ariadna Boloix Amenós, Carlos Jimenez Jimenez, Gabriel Gallo Oller, Luís Gros Subias, Gabriela Guillén Burrieza, Thaïs Murciano Carrillo, Maria Oliveras Arenas, Constantino Sábado Álvarez, M Luz Uria Oficialdegui, Patricia Zarzosa Martinez and Maria J Pérez.

PhD Students
Anna Collado Gimbert, Alba Fernández Gómez, Victoria Gutierrez Valle, Raquel Hladun Alvaro, Amira Idrizovic, Marta Palau Requena, Guillem Pons Barcons, Valeria Rizzuto, Júlia Sansa Girona, Lorena Valero Arrese and Pablo Velasco Puyó

Lab Technicians
Ainara Magdaleno Cazon

Nursing and Technical Staff
Carlota Aguilera Ordoñez, Elena Andretta, Raquel Andreu Vilarroig, Raquell Anta Peña, M Isabel Benitez Carabante, Marina Bonfill Ralló, M Eugenia Bustelo Almeida, Claire Diot, Ariadna García Rodríguez, Laura Murillo Sanjuan, M de los Ángeles Rodríguez Sánchez, Anna Salo Rovira, Cristina Valles Valles and Andrea Vilaplana Blanes

52

PUBLICATIONS

482

IMPACT FACTOR

9.27

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Gungor T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M, von Stackelberg A, Balduzzi A, Corbacioglu S, Bader P and Diaz-de-Heredia C
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
J Clin Oncol. 2021 Feb 1;39(4):295-307.
DOI: doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17.
IF: 44.544

Laetsch TW, DuBois SG, Bender JG, Macy ME and Moreno L
Opportunities and Challenges in Drug Development for Pediatric Cancers.
Cancer Discov. 2021 Mar;11(3):545-559.
DOI: doi: 10.1158/2159-8290.CD-20-0779. Epub 2020 Dec 4.
IF: 39.397

Masanas M, Masia N, Suarez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jimenez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guillen G, Navarro A, Llobet-Navas D, Villanueva A, Sanchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A and Segura MF
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Clin Transl Med. 2021 Oct;11(10):e533.
DOI: doi: 10.1002/ctm2.533.
IF: 11.492

Giralt I, Gallo-Oller G, Navarro N, Zarzosa P, Pons G, Magdaleno A, Segura MF, Sabado C, Hladun R, Arango D, Sanchez de Toledo J, Moreno L, Gallego S and Roma J
Dickkopf-1 Inhibition Reactivates Wnt/beta-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo.
Int J Mol Sci. 2021 Nov 29;22(23).
DOI: doi: 10.3390/ijms222312921.
IF: 5.924

Alonso L, Mendez-Echevarria A, Rudilla F, Mozo Y, Soler-Palacin P, Sisinni L, Bueno D, Riviere J, de Paz R, Sanchez-Zapardiel E, Querol S, Rodriguez-Pena R, Lopez-Granados E, Gimeno R, Diaz de Heredia C and Perez-Martinez A
Failure of Viral-Specific T Cells Administered in Pre-transplant Settings in Children with Inborn Errors of Immunity.
J Clin Immunol. 2021 May;41(4):748-755.
DOI: doi: 10.1007/s10875-020-00961-w. Epub 2021 Jan 18.
IF: 8.317

A Phase I trial of ABTL0812 in children with relapsed/refractory neuroblastoma and extra-cranial solid tumors
Principal Investigator: Lucas Moreno Martín-Retortillo
Agency: Instituto de Salud Carlos III
Funding: 826,760.77 €
Period: 2022-2025

SEHOP-PENCIL Study: Personalised Medicine for Cancer in Children in Spain
Principal Investigator: Lucas Moreno Martín-Retortillo
Agency: Instituto de Salud Carlos III
Funding: 1,025,179 €
Period: 2022-2025

Development of a new therapeutic target with high anti-oncogenic potential in childhood sarcomas: the pharmacological blockade of the Hedgehog co-receptor CDO
Principal Investigator: Josep Roma
Agency: Instituto de Salud Carlos III
Funding: 122,815 €
Period: 2022-2024

COMIK 2.0: Integration of a genomic and functional screening platform for paediatric precision oncology
Principal Investigator: Lucas Moreno Martín-Retortillo & Aroa Soriano Fernández
Agency: Instituto de Salud Carlos III
Funding: 214,170 €
Period: 2022-2024

BEACON BIO
Principal Investigator: Lucas Moreno Martín-Retortillo
Agency: European Science Foundation
Funding: 104,500 €
Period: 2022-2023

Oncology

Research Areas